SEC filing · 8-K

REGENXBIO Inc.: Material agreement

REGENXBIO entered into a patent litigation settlement agreement with Sarepta Therapeutics and will receive a $39.0 million payment.

Filed September 23, 2026

Positive for the company

What happened

On September 23, 2026, REGENXBIO and the University of Pennsylvania entered into a Settlement Agreement with Sarepta Therapeutics and Catalent.

The full interpretation is in the app

Why it matters, the key numbers from the document and what to watch next: the full interpretation of every report is part of Pro.

Read the full interpretation

Read the original

Filing document on SEC.gov All documents of this filing

Back to REGENXBIO Inc.

Summary generated automatically from the filing text and checked against it: every number above is printed in the document. It describes the filing and is not investment advice. Read the original before relying on it.